Abstract 178P
Background
Lenvatinib (LEN) has demonstrated the efficacy and safety in patients (pts) with advanced HCC (aHCC) as first-line treatment in the pivotal REFLECT trial. Further evaluation in real-world setting is necessary to measure the clinical outcomes of LEN in daily practice.
Methods
This is a multicenter retrospective analysis from 3 Korean referral cancer institutions. Between September 2018 and November 2019, a total of 86 pts received LEN for the management of BCLC B or C aHCC, and 75 pts who had at least one follow-up visit after the start of LEN were included in this analysis.
Results
Median age was 59 years (range, 19-81), and 56 pts (74.7%) were male. Baseline characteristics were as follows; Child-Pugh class A/B in 57 (76.0%)/18 (24.0%), BCLC B/C in 9 (12.0%)/66 (88.0%), prior systemic therapy in 24 (32.0%) including 14 (18.7%) with prior immune checkpoint inhibitors (ICIs). LEN was used as 1st/2nd/3rd-4th lines of therapy in 51 (68.0%)/13 (17.3%)/11 (14.7%) pts, and 30 (40.0%) had extensive disease extent excluded in the REFLECT trial. In overall pts, the median follow-up duration was 4.7 months (mo) (95% CI, 3.3-6.2), the median PFS and OS were 4.6 (95% CI, 3.6-5.6) and 6.7 mo (95% CI, 5.0-8.3), repectively. In Child-Pugh A group, the PFS and OS were as follows: 1st line setting, 4.6 (95% CI,3.1-6.1) and 10.7 mo (95% CI, 4.7-16.6); >= 2nd line setting, 4.4 (95% CI, 2.8-6.0) and 6.4 mo (95% CI,4.7-8.0); prior ICI group 4.4 (95% CI, 3.6-5.1) and 7.1 mo (95% CI, 5.7-8.5), respectively. In Child-Pugh B group, the PFS and OS were 2.6 (95% CI, 0.6-4.6) and 5.3 mo (95% CI, 2.0-8.5), respectively. According to the RECIST v 1.1, response rates and disease control rate were 10.7% and 77.4%, respectively, in overall pts. The most common grade 3-4 toxicities were hyperbilirubinemia (n=8, 10.7%), AST elevation (n=6, 8.0%) and diarrhea (n=4, 5.3%).
Conclusions
LEN was effective and well tolerated in pts with aHCC in Korean real-life setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Yoo: Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Ipsen; Advisory/Consultancy: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session